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Methods: 98 tissue samples from resected primary squamous cell 
carcinoma (SCC) (n=50) and adenocarcinoma (AC) (n=48) tumours 
were analysed. We compared ACs and SCCs from patients who 
remained disease-free for at least three years (“non-recurrent”) with 
those from patients whose disease recurred within 18 months (“recur-
rent”). Tumour DNA was hybridised against female human genomic 
DNA to a Whole Genome aCGH platform containing ~43,000 probes. 
Copy-number was validated in two genes, GSTM1 and GSTT1, using 
quantitative real-time PCR to determine the reliability of the aCGH 
data. Genomic regions with signiﬁcant copy-number variation (CNV) 
(DNA gain/loss) were identiﬁed with an aberration detection algorithm. 
CNVs were compared between recurrent and non-recurrent tumours 
to identify signiﬁcantly discriminant regions (χ2, p<0.05). To correlate 
copy-number with gene expression, published whole-genome expres-
sion data [Larsen et al (2006) Carcinogenesis; Larsen et al (2007) Clin 
Cancer Res] was correlated with aCGH data. A supervised analysis 
identiﬁed genes signiﬁcantly differentially expressed between recurrent 
and non-recurrent tumours (p<0.05).
Results: Common regions of CNV (>50% of tumours, irrespective of 
recurrence status) frequently observed in ACs and SCCs were gain of 
1q, 3q and 5p and loss of 3p, 6q, 8p and 9p. Putative recurrence-associ-
ated aberrations were deﬁned as regions with frequent CNV (>20%) 
with signiﬁcant differences in the aberration frequency between tumour 
recurrence groups (>15%). In ACs, 15 CNVs discriminated between 
recurrence groups, including gain of 8p11.21-q11.1, 9q34.3, 10p15.3, 
and several regions along 7q and 21q11.2-q21.1 loss (more frequent in 
recurrent tumours) and 4p13-4p12 gain and 14q23.3-q32.33 loss (more 
frequent in non-recurrent ACs). In SCCs, 17 CNVs differed between 
recurrence groups, including 2q22.1-q24.2 and 8q24.3 gain (recur-
rent tumours) and 3p26.3-p24.3 and 8p23.1-8p12 loss (non-recurrent 
tumours) (p<0.05, χ2). Three putative aberrations were identiﬁed in 
both histological subtypes: 8p11.21, 9p21.1-p21.3, and 1p34.1-p33. 
Using gene expression microarray data, genes signiﬁcantly differen-
tially expressed between recurrence groups (p<0.05) were mapped to 
their genomic location. Those located in putative recurrence-associated 
CNVs (15 and 17 in ACs and SCCs, respectively) with high correlation 
between copy-number and expression (r=0.4-0.8) include 7q21.3-
7q32.32 (CYP3A7, CAV2, and WASL), 10p15.3-p11.21 (SVIL, TCF3, 
and RAB18), and 14q23.3-14q32.33 (MARK3, BAG5, SIVA, and 
MTA1).
Conclusions: This study used a whole-genome approach to charac-
terise primary NSCLCs in relation to tumour recurrence. High-resolu-
tion aCGH analysis of NSCLCs identiﬁed focal genomic aberrations 
signiﬁcantly associated with disease recurrence. Integration of gene 
expression data with aCGH data enabled the detection of several genes 
with copy-number driven expression. Genes located in these regions 
may represent novel oncogenes or tumour suppressor genes and are 
currently being validated in an independent set of tumours.
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Genomic study: Genome-wide deletion analysis enables the delinea-
tion of the likely locations of tumor suppressor genes (TSG) and could 
provide molecular markers for disease classiﬁcation. To deﬁne the 
minimal deletion regions (MDRs) in lung cancer, we used 92 microsat-
ellite markers spanning 29 regions in 36 lung squamous cell carcinoma 
(SCC) patients designed to verify the maximal contiguous deletion 
loci. Eight MDRs were found. The candidate genes GAS7 and OVCA2 
in the MDR17pA (17p13.1-p13.2) were further examined for mRNA 
expression. Low expression of the GAS7 gene in 57% of patients ana-
lyzed suggested its importance in lung SCC tumorigenesis. In addition, 
we found a panel of ﬁve microsatellites, which can be used as prog-
nostic biomarkers in lung cancer. Furthermore, alteration in more than 
two genes in the p53 damage response gene and in the double-strand 
break (DSB) repair genes, BRCA1 and XRCC5 was more apparent in 
high chromosome instability patients showing as high fractional allelic 
loss (FAL) than in low FAL patients. Our results provide biomarkers 
that may be used for monitoring tumor progression and for positional 
cloning of new TSGs. Our data show direct evidence that alterations in 
DSB repair and damage response pathways is involved in the genomic 
instability veriﬁed by intensive microsatellites of lung cancer.
Epigenomic study: We established a genome-wide hypermethyl-
ation analysis using the microarray-based strategy called differential 
methylation hybridization (DMH) containing ~8,000 CpG islands to 
identify the regions of hypermethylation in 30 lung cancer patients. The 
genes located in these methylated regions were further identiﬁed by 
the BLAST method. Common methylated genes at the stage-speciﬁc 
manner were identiﬁed. Several genes were speciﬁcally associated 
with adenocarcinoma or squamous lung cancer patients, which are two 
major subtypes of lung cancer. These methylated genes were further 
conﬁrmed for their low mRNA expression in 20 patients. Overexpres-
sion of DNA 5’-cytosine-methyltransferase 1 (DNMT1) has been 
reported in various cancers. However, the mechanism underlying over-
expression of DNMT1 and to the “methylator” phenotype we observed 
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remains unclear. We performed DNMT1 promoter luciferase assay 
and found that wild type p53 could negatively regulate the DNMT1 
promoter, whereas mutant p53 could activate DNMT1 promoter activ-
ity. The physical binding of wild type p53 and mutant p53 to DNMT1 
promoters was identiﬁed by chromatin immunoprecipitation. These 
data suggest that deregulation of DNMTs is associated with the loss of 
transcriptional repression of p53. The p53 mutation results in overex-
pression of DNMT1 and hypermethyaltion of target tumor suppressor 
genes and ultimately leads to tumorigenesis.
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Female-non-smokers with lung adenocarcinomas is becoming promi-
nent among Asian patients with lung cancer. The clinical parameters 
of gender, smoking habits, tumor histology, ethnic origin and EGFR 
mutation status were identiﬁed as predictors of clinical response to 
targeted therapy. The aim of this study was to identify the gene expres-
sion proﬁles of lung adenocarcinomas compared to normal lungs, with 
respect to gender difference, smoking habits and tumor EGFR mutation 
status among Hong Kong Chinese patients with lung adenocarcinomas. 
Total RNA extracted from 49 lung adenocarcinomas and 9 normal lung 
tissues and hybridized onto Affymetrix GeneChip HG-U133 Sets. Data 
were normalized and subjected to repeated iterations of unsupervised 
hierarchical clustering, with independent validation microarray data 
sets, for identiﬁcation of stable sample clustering, followed by super-
vised analysis with Signiﬁcance Analysis of Microarray (SAM) and 
Support Vector Machine (SVM) for identiﬁcation of molecular classi-
ﬁers with respect to sample clustering results. Unsupervised hierarchi-
cal clustering revealed stable clustering of adenocarcinomas vs normal 
lungs, female-non-smokers vs other tumors, and tumors bearing EGFR 
mutation at exons 18 - 21 vs wildtype tumors. Supervised analysis 
identiﬁed discriminatory gene classiﬁers that predict lung adenocarci-
nomas (gene classiﬁers = 27, prediction sensitivity and speciﬁcity of 
100%), female non-smokers (gene classiﬁers = 22, prediction sensitiv-
ity of 65 - 85% and speciﬁcity of 84 - 94% with different independent 
validation sets) and EGFR mutation status (gene classiﬁers = 26, 
prediction sensitivity and speciﬁcity of 100%). Our data suggested that 
there is a group of Chinese female non-smokers with lung adenocarci-
nomas which displays gene expression proﬁles distinct from pulmonary 
adenocarcinomas from patients with other clinical characteristics. The 
identiﬁcation of gene classiﬁers could provide information for further 
study on lung adenocarcinomas, female non-smokers with lung cancer 
and lung tumors bearing EGFR mutations.
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Background: Peutz-Jeghers syndrome has been associated with muta-
tions in the LKB1 tumor suppressor gene. Somatic mutations of LKB1 
gene have been found in human cancers including non-small cell lung 
cancer (NSCLC) with adenocarcinoma histology. Reports with small 
number of cell lines and tumors have suggested the prevalence of 
LKB1 mutations in NSCLC to be ~30%. Relation of LKB1 mutations 
to the patient gender, age, smoking history, tumor stage and outcome, 
and their relationship to other commonly mutated genes in NSCLC is 
unknown. 
Methods: NSCLC tumor specimens (n = 167) with adenocarcinoma 
(n = 161) and adenosquamous carcinoma histologies (n = 6) were col-
lected from surgical resections and RNA was extracted using routine 
methods. Some of the specimens (n = 63) were collected in Korea, 
while rest of the specimens (n = 104) came from Caucasian patients 
from the US. Tumors were screened for LKB1 mutations using the 
SURVEYOR-WAVE method. In SURVEYOR-WAVE method, the 
whole coding region of LKB1 gene was PCR ampliﬁed in two overlap-
ping amplicons, PCR products were digested with SURVEYOR-en-
zyme which cleaves mismatches, and the specimens were analyzed 
with sensitive HPLC method for shorter digestion products. If digestion 
products were present, the specimen was sequenced using Sanger 
method to verify the mutation. Mutational analysis K-Ras, B-Raf, and 
EGFR hotpots were done either by SURVEYOR-WAVE method analo-
gously to LKB1 gene analysis or by direct sequencing with Sanger 
method. Statistical comparisons were done using Fisher’s exact test, p 
values < 0.05 were considered signiﬁcant 
Results: Mutations of the LKB1 gene were detected in twenty-two 
tumors (13%). Interestingly, twenty of the LKB1 mutations were 
detected in specimens collected in U.S. (prevalence 19%) while only 
two mutations (prevalence 3%) were detected in specimens from Asian 
origin (p = 0.004). The mutations were mainly deletions and insertions 
(82%) but some missense (9%), and nonsense (9%) mutations were 
also found. No correlation of LKB1 mutations to gender, age, or stage 
